UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of Earliest Event Reported): July 1, 2005


                            IRIS INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)


         DELAWARE                     001-11181               94-2579751
(State or other jurisdiction        (Commission            (I.R.S. Employer
     of incorporation)               File Number)          Identification No.)


                                9172 ETON AVENUE
                              CHATSWORTH, CA 91311
                (Address of Principal Executive Offices/Zip Code)


                                 (818) 709-1244
              (Registrant's telephone number, including area code)


         Check the  appropriate  box below if the Form 8-K filing is intended to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

         |_|      Written   communications   pursuant  to  Rule  425  under  the
                  Securities Act (17 CFR 230.425)

         |_|      Soliciting material pursuant to Rule 14a-12 under the Exchange
                  Act (17 CFR 240.14a-12)

         |_|      Pre-commencement  communications  pursuant  to  Rule  14d-2(b)
                  under the Exchange Act (17 CFR 240.14d-2(b))

         |_|      Pre-commencement  communications  pursuant  to Rule  13e-4(c))
                  under the Exchange Act (17 CFR 240.13e-4c))





ITEM 5.02.        DEPARTURE  OF DIRECTORS  OR  PRINCIPAL  OFFICERS;  ELECTION OF
                  DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

         Effective July 1, 2005, our Board of Directors appointed Bernard "Dino"
M. Alfano (age 44) as President of its newly created Diagnostics  Business Unit.
Mr.  Alfano joined us in December  2001 as Director of  International  Sales and
Marketing.  Following his promotion to International Vice President in June 2003
and  subsequent  elevation  to Vice  President  of Global  Sales and  Service in
September 2004, he was responsible for the international  launch of our iQ(R)200
product platform that led to increased market penetration, record sales, revenue
and profit for our  Diagnostics  Division in 2004.  Prior to  December  2001 Mr.
Alfano assisted us with the iQ(R)200  market research and product  branding as a
consultant,  and from  January  2000 to June 2001,  served as Vice  President of
Business and Product  Development  for Oxibio,  Inc. Mr.  Alfano has 19 years of
experience in medical devices and  diagnostics  with companies such as Johnson &
Johnson, C.R. Bard and Syntex.

         There are no understandings or arrangements  between Mr. Alfano and any
other person pursuant to which Mr. Alfano was appointed as an executive officer.
Mr. Alfano does not have any family  relationship  with any director,  executive
officer  or person  nominated  or chosen by our Board of  Directors  to become a
director or executive officer. Additionally, there have been no transactions, or
series of related  transactions,  in the last year,  nor is there any  currently
proposed transaction,  or series of similar transactions,  to which we or any of
our subsidiaries was a party, or will be a party, and in which Mr. Alfano or any
member of his immediate family had, or will have, a direct or indirect  material
interest.

         A press release announcing Mr. Alfano's  appointment is attached hereto
as Exhibit 99.1.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS


         (c)      Exhibits.

                  The following exhibits are filed herewith:

                  EXHIBIT
                  NUMBER   DESCRIPTION
                  -------  -----------

                  99.1     Press Release  announcing the  Appointment of Bernard
                           "Dino" M. Alfano as President of IRIS  International,
                           Inc.'s Diagnostics Business Unit, dated July 5, 2005.


                                       2



                                    SIGNATURE

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                          IRIS INTERNATIONAL, INC.



Date:    July 7, 2005                     By:  /s/ Martin G. Paravato
                                               -----------------------------
                                               Martin G. Paravato
                                               Chief Financial Officer


                                       3



                                  EXHIBIT INDEX

         EXHIBIT
         NUMBER                            DESCRIPTION
         -------      ----------------------------------------------------------

           99.1       Press Release announcing the Appointment of Bernard "Dino"
                      M.  Alfano  as  President  of IRIS  International,  Inc.'s
                      Diagnostics Business Unit, dated July 5, 2005.


                                       4